Literature DB >> 10074939

Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors.

B Lovejoy1, A R Welch, S Carr, C Luong, C Broka, R T Hendricks, J A Campbell, K A Walker, R Martin, H Van Wart, M F Browner.   

Abstract

The X-ray crystal structures of the catalytic domain of human collagenase-3 (MMP-13) and collagenase-1 (MMP-1) with bound inhibitors provides a basis for understanding the selectivity profile of a novel series of matrix metalloprotease (MMP) inhibitors. Differences in the relative size and shape of the MMP S1' pockets suggest that this pocket is a critical determinant of MMP inhibitor selectivity. The collagenase-3 S1' pocket is long and open, easily accommodating large P1' groups, such as diphenylether. In contrast, the collagenase-1 S1' pocket must undergo a conformational change to accommodate comparable P1' groups. The selectivity of the diphenylether series of inhibitors for collagenase-3 is largely determined by their affinity for the preformed S1' pocket of collagenase-3, as compared to the induced fit in collagenase-1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074939     DOI: 10.1038/6657

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  42 in total

Review 1.  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.

Authors:  Klaus Maskos; Wolfram Bode
Journal:  Mol Biotechnol       Date:  2003-11       Impact factor: 2.695

2.  Structure of human ADAM-8 catalytic domain complexed with batimastat.

Authors:  Troii Hall; Huey Sheng Shieh; Jacqueline E Day; Nicole Caspers; Jill E Chrencik; Jennifer M Williams; Lyle E Pegg; Adele M Pauley; Andrea F Moon; Joseph M Krahn; David H Fischer; James R Kiefer; Alfredo G Tomasselli; Marc D Zack
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-05-22

Review 3.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

4.  Binary image representation of a ligand binding site: its application to efficient sampling of a conformational ensemble.

Authors:  Edon Sung; Sangsoo Kim; Whanchul Shin
Journal:  BMC Bioinformatics       Date:  2010-05-18       Impact factor: 3.169

5.  Molecular docking and inhibition of matrix metalloproteinase-2 by novel difluorinatedbenzylidene curcumin analog.

Authors:  Aamir Ahmad; Afreen Sayed; Kevin R Ginnebaugh; Vivek Sharma; Anita Suri; Arundhati Saraph; Subhash Padhye; Fazlul H Sarkar
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

Review 6.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

7.  Anacardic acid inhibits the catalytic activity of matrix metalloproteinase-2 and matrix metalloproteinase-9.

Authors:  Athira Omanakuttan; Jyotsna Nambiar; Rodney M Harris; Chinchu Bose; Nanjan Pandurangan; Rebu K Varghese; Geetha B Kumar; John A Tainer; Asoke Banerji; J Jefferson P Perry; Bipin G Nair
Journal:  Mol Pharmacol       Date:  2012-06-28       Impact factor: 4.436

8.  Solution structure of inhibitor-free human metalloelastase (MMP-12) indicates an internal conformational adjustment.

Authors:  Rajagopalan Bhaskaran; Mark O Palmier; Nusayba A Bagegni; Xiangyang Liang; Steven R Van Doren
Journal:  J Mol Biol       Date:  2007-10-16       Impact factor: 5.469

9.  Ligand-induced expansion of the S1' site in the anthrax toxin lethal factor.

Authors:  Kimberly M Maize; Elbek K Kurbanov; Rodney L Johnson; Elizabeth Ambrose Amin; Barry C Finzel
Journal:  FEBS Lett       Date:  2015-11-11       Impact factor: 4.124

10.  The role of p300 histone acetyltransferase in UV-induced histone modifications and MMP-1 gene transcription.

Authors:  Min-Kyoung Kim; Jung-Min Shin; Hee Chul Eun; Jin Ho Chung
Journal:  PLoS One       Date:  2009-03-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.